PRGN-3006 Adoptive Cellular Therapy for Relapsed or Refractory AML or High Risk MDS
Status:
Recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
This is a first-in-human dose escalation/dose expansion study to evaluate safety and identify
best dose (or recommended Phase 2 dose) of modified immune cells, PRGN-3006 (autologous
chimeric antigen receptor (CAR) T cells), in adult patients with relapsed or recurred acute
myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic
leukemia (CMML). Autologous CAR T cells are modified immune cells that have been engineered
in the laboratory to specifically target a protein found on tumor cells and kill them.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute PGEN Therapeutics, Inc., a subsidiary of Precigen, Inc.